Drugs / Polyethylene Glycol Losenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05611684 | Jun 2022 → Dec 2023 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene Glycol Losenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05611684 ↗ |